Compare LMND & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LMND | AMRX |
|---|---|---|
| Founded | 2015 | 2002 |
| Country | United States | United States |
| Employees | 1282 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.0B |
| IPO Year | N/A | 2018 |
| Metric | LMND | AMRX |
|---|---|---|
| Price | $62.62 | $17.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $70.86 | $15.60 |
| AVG Volume (30 Days) | 1.5M | ★ 2.2M |
| Earning Date | 04-29-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 157.89 |
| EPS | N/A | ★ 0.19 |
| Revenue | N/A | N/A |
| Revenue This Year | $65.20 | $4.48 |
| Revenue Next Year | $33.31 | $7.13 |
| P/E Ratio | ★ N/A | $90.68 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $35.70 | $7.67 |
| 52 Week High | $99.90 | $17.86 |
| Indicator | LMND | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 62.02 | 82.17 |
| Support Level | $50.37 | $12.46 |
| Resistance Level | $72.31 | N/A |
| Average True Range (ATR) | 3.84 | 0.66 |
| MACD | 0.50 | 0.13 |
| Stochastic Oscillator | 94.72 | 86.85 |
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes. The company is using technology, data, artificial intelligence, contemporary design, and social impact to deliver delightful and affordable insurances. The Company operates in one report segment providing personal property and casualty insurance products within the United States and Europe, including the UK.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.